Adverse events in small dogs treated with a single dose of vinblastine
Journal of Veterinary Internal Medicine · 02.03.2026 · 40 (2)
DOI: 10.1093/jvimsj/aalag050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 30.03.2026. Verfasst von Fukiko Matsuyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Small Animal Cancer Center, Japan Small Animal Medical Center, 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023, Japan. Hauptthemen laut MEDLINE: Vinblastine, Neoplasms, Dog Diseases. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Vinblastine (VBL) is a chemotherapeutic agent commonly used to treat malignant tumors in dogs. Although a maximum tolerated dose of 3.5 mg/m2 has been reported, the safety and tolerability of this dose in small dogs remain inadequately characterized. Hypothesis/Objectives Retrospectively evaluate adverse events (AEs) associated with a single IV administration of VBL at a dosage of 2.0 mg/m2 in dogs weighing < 10 kg. We hypothesized that AE occurrences in small dogs would be comparable to those reported in phase I studies involving larger breeds. Animals Forty client-owned dogs weighing < 10 kg with malignant tumors.
Methods
Adverse events after a single IV VBL administration at a dosage of 2.0 mg/m2 were retrospectively evaluated in small dogs with malignant tumors. Myelosuppressive and gastrointestinal AEs were graded using VCOG-CTCAE v2.0 criteria.
Results
Neutropenia and thrombocytopenia were observed in 82.5% (33/40) and 5.0% (2/40) of dogs, respectively. Grade 3 or 4 neutropenia occurred in 32.5% (13/40), comprising 15.0% (6/40) with Grade 3 and 17.5% (7/40) with Grade 4 events. Inappetence, vomiting, and diarrhea were reported in 7.5% (3/40), 7.5% (3/40), and 25.0% (10/40) of dogs, respectively, and were generally mild. Febrile neutropenia was noted in 5.0% (2/40) of dogs. Conclusions and clinical importance Vinblastine administered at a dosage of 2.0 mg/m2 in small dogs with malignant tumors resulted in gastrointestinal toxicity within clinically acceptable limits, but close monitoring for neutropenia is warranted. These findings suggest that dose escalation of VBL, as reported in larger dogs, may not be feasible in smaller dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Small Animal Cancer Center, Japan Small Animal Medical Center, 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023, Japan.
Zitieren
APA
Matsuyama, F., Harada, K., Ichimata, M., Fukazawa, E., Katayama, R., & Kobayashi, T. (2026). Adverse events in small dogs treated with a single dose of vinblastine. Journal of Veterinary Internal Medicine, 40(2). https://doi.org/10.1093/jvimsj/aalag050
Vancouver
Matsuyama F, Harada K, Ichimata M, Fukazawa E, Katayama R, Kobayashi T. Adverse events in small dogs treated with a single dose of vinblastine. Journal of Veterinary Internal Medicine. 2026;40(2). doi:10.1093/jvimsj/aalag050
BibTeX
@article{Matsuyama2026,
author = {Matsuyama, Fukiko and Harada, Kei and Ichimata, Masanao and Fukazawa, Eri and Katayama, Ryuzo and Kobayashi, Tetsuya},
title = {Adverse events in small dogs treated with a single dose of vinblastine},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {2},
doi = {10.1093/jvimsj/aalag050}
}
EUVIMED